Principal Investigator
David Baidal
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250654
Clinical Trial Summary
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other